Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 800 results for "kexin"

Sichuan Kexin Mechanical and Electrical Equipment issues H1 20...

:Sees net profit outlook for H1 of 2015 to increase 171.54 pct to 198.69 pct, or to be about 4 mln yuan to about 4.4 mln yuan.Says the net profit of H1 2014 was 1.4731 mln yuan.Comments that increased orders and decreased expense are the main ... Reuters, 4 weeks ago
Monthly Prescribing Reference

PCSK9 inhibitors lower cholesterol, but is cost a concern?

The FDA's approval of the first proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor brought about excitement for some with regards to the effectivenss of the new class of drugs in lowering cholesterol. It also raised concerns about the ...
 Cardiovascular Business1 week ago First-in-Class Cholesterol Drug Approved by FDA  AAPS Pharmceutica6 days ago Study: 80% of Cardiovascular Patients Significantly Underuse Statins  Pharmscope1 week ago Early FDA Review Mostly Favorable for Alirocumab  Dermatology Online Journal1 month ago
Securities Technology Monitor

New study: 80% of people with established cardiovascular disease significantly underuse statins

/PRNewswire/ --The first of two cholesterol-lowering PCSK9 inhibitors (Proprotein Convertase Subtilisin/Kexin type 9) is expected to be approved by the U.S. Food and Drug Administration (FDA) as early as this week. To guide its utilization ...
 MoneyShow.com2 weeks ago Masimo Corporation (MASI) Release: New Study: 80% Of People With Established Cardiovascular Disease Significantly Underuse Statins 7/21/2015  ClinicSpace2 weeks ago Masimo Corporation Release: New Study: 80% Of People With Established Cardiovascular Disease Significantly Underuse Statins  BioSpace2 weeks ago

Regeneron/Sanofi's Praluent Gets Positive FDA Panel Vote

Regeneron Pharmaceuticals, Inc. REGN and its partner Sanofi's SNY PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody, Praluent, was recommended by the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA.The EMDAC ...
 Individual.com1 month ago Regeneron and Sanofi Report Positive Data on Praluent  Zacks.com3 weeks ago

Worldwide: Starwood Goes Eco-Friendly Commercial Property Executive

June 19, 2015 Possessed by Suzhou Science Town Kexin Cultural Tourism Development Co., the 188-key hotel targets the current, eco-conscious traveler by integrating an array of eco-friendly features. It features the very first-of-its-kind keyless ...
 NewsListOnline1 month ago Starwood launches eco-hotel in Suzhou, China  Climate Action1 month ago Starwood announces debut of its Element brand in Asia Pacific  Bloomberg1 month ago Starwood unveils Element Suzhou Science and Technology Town in China  Individual.com1 month ago

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia

Terms of Use The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property ...
 Annals of Internal Medicine1 day ago PCSK9 inhibitors: What you should know  Orthopedics Today1 month ago Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)  PharmCast1 month ago Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?  Journal of the American College of Cardiology1 month ago

FDA advisory panel recommends approval of second PCSK9 inhibitor in two days

An FDA advisory panel on June 10 recommended the approval of evolocumab, a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor intended to reduce low-density lipoprotein cholesterol and improve other lipids. All 15 members of the ...
 Cardiovascular Business1 month ago FDA approves new cholesterol-lowing drug  American Nurse Today5 days ago REGENERON PHARMACEUTICALS : and Sanofi Announce CHMP Recommends European Approval of Praluent® alirocumab for the Treatment of Hypercholesterolemia  4 Traders6 days ago FDA Approves Specialty Medication, Praluent, for Cholesterol  Pharmacy Practice News1 week ago
Pharmaceutical Manufacturing Magazine

Amgen's PCSK9 Inhibitor, Repatha, Wins EC Nod

The European Commission (EC) granted marketing authorization to Amgen's proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) on July 21, 2015 for the treatment of hypercholesterolemia (heterozygous familial and ...
 BioPharm International2 weeks ago European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol  FierceBiotech1 week ago Critical Milestone for Patients With Uncontrolled Cholesterol who Require Additional Intensive LDL-C Reduction  PharmaVOICE1 week ago Amgen Beats Regeneron, Sanofi on Cholesterol Drug  Pharmaceutical Manufacturing Magazine1 week ago

Premarket Biotech Digest: The PCSK9 Race, AbbVie Earnings, Inotek Jumps 200%

Dr De's Opening Thoughts: The Cholesterol Countdown The proprotein convertase subtilisin kexin 9 (PCSK9) enzyme is responsible for increasing LDL-C in the body by reducing a protein that metabolizes cholesterol. PCSK9 inhibitors are monclonal ...
 TeleTrader.com1 week ago
China Daily Asia

Avocados find sweet spot for surge in growth

Zhang Kexin is in her mid-20s and works in the public relations department of a State-owned company. But she still remembers the first time she tasted avocados. Her first contact with the fruit was when she was in primary school after a close ... month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less